Switching from triple combination treatment to protease inhibitor monotherapy may increase the risk of elevations in @entity645 RNA, and is not recommended in most international treatment guidelines. However, the use of protease inhibitor monotherapy could prevent or reverse adverse events related to long-term use of @entity2353 analogues, such as @entity3388 , renal adverse events, @entity2331 , and @entity417 . A detailed MEDLINE search was conducted to identify randomized clinical trials of triple-combination treatment versus protease inhibitor monotherapy with detailed analyses of safety. Summary results from analysis of changes in body composition, changes in lipids, renal adverse events, and @entity417 were evaluated for @entity1 taking either protease inhibitor monotherapy or triple therapy. In six trials with dual-energy X-ray absorptiometry data available, the percentage of @entity1 with @entity3388 was significantly lower in the protease inhibitor monotherapy arms than the triple therapy arms (p = 0.03). In these trials there was also no significant difference in the risk of lipohypertrophy between protease inhibitor monotherapy and triple therapy arms. In one trial there was a higher risk of renal adverse events for @entity1 taking @entity15833 in the triple therapy arm. In two trials there were rises in total @entity165 when @entity1 stopped taking @entity15833 in the protease inhibitor monotherapy arms. In conclusion, there is a mixed pattern of changes in @entity2353 analogue-related adverse events after switching from triple therapy to protease inhibitor therapy. The potential for safety benefits of stopping @entity2353 analogues needs to be set against a higher risk of @entity645 RNA elevations during protease inhibitor monotherapy.

Effects of Switching To Protease Inhibitor Monotherapy on XXXX Analogue-Related Adverse Events.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2353 :: ('CHEBI:33838', 'Chemical') :: ['nucleoside'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity645 :: ('57667', 'Species') :: ['HIV'] @entity2331 :: ('MESH:D001851', 'Disease') :: ['osteopenia'] @entity3388 :: ('MESH:C535905', 'Disease') :: ['lipoatrophy'] @entity15833 :: ('MESH:C096918', 'Chemical') :: ['tenofovir'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity2353 :: (CHEBI:33838,Chemical) :: ['Nucleoside']
